Pembrolizumab (Keytruda®) is indicated in combination with pemetrexed and platinum chemotherapy, for the first-line treatment of metastatic non-squamous NSCLC in adults whose tumours have no EGFR or ALK positive mutations.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||14/08/2018|
|Rapid review completed||29/08/2018|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard of care.|
|Full pharmacoeconomic assessment commissioned by HSE||14/09/2018|
|Pre-submission consultation with Applicant||22/10/2018|
|Submission received from Applicant||20/12/2018|
|Preliminary review sent to Applicant||14/06/2019|
|NCPE assessment re-commenced||10/07/2019|
|Factual accuracy sent to Applicant||31/07/2019|
|NCPE assessment re-commenced||09/08/2019|
|NCPE assessment completed||15/08/2019|
|NCPE assessment outcome||The NCPE recommends that pembrolizumab (Keytruda®), prescribed in combination with platinum chemotherapy plus pemetrexed for the first line treatment of non-squamous NSCLC, be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments.*|
*This recommendation should be considered while also having regard to the criteria
specified in the Health (Pricing and Supply of Medial Goods) Act 2013.